<DOC>
	<DOC>NCT00002047</DOC>
	<brief_summary>To evaluate the safety, tolerance, and pharmacokinetics of Retrovir (AZT) administration in HIV-infected patients in renal failure receiving maintenance hemodialysis.</brief_summary>
	<brief_title>Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal Failure</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Patients must have: A positive HIV antibody test (ELISA confirmed by Western blot). Chronic renal failure managed by a stable hemodialysis regimen. Acceptable hepatic function defined by specified lab values. Life expectancy &gt; 6 months. Enrollment is limited to 9 chronic hemodialysis patients and 9 Continuous Ambulatory Peritoneal Dialysis (CAPD) patients. These patients must be stable in their ESRD treatment regimen before entry. Exclusion Criteria Coexisting Condition: Patients with the following are excluded: Active, serious opportunistic infections at the time of study entry. Fever &gt; 100 degrees F at study entry. Severe malabsorption (evidenced by persistent diarrhea of greater than 4 weeks duration with = or &gt; 6 loose stools per day accompanied by significant weight loss). Patients with the following are excluded: Active, serious opportunistic infections at the time of study entry. Fever &gt; 100 degrees F at study entry. Severe malabsorption (evidenced by persistent diarrhea of greater than 4 weeks duration with = or &gt; 6 loose stools per day accompanied by significant weight loss). Prior Medication: Excluded within 2 weeks of study entry: Any other experimental therapy. Drugs which cause significant bone marrow suppression. Rifampin or rifampin derivatives. Cytolytic chemotherapy. Drugs which cause significant hepatotoxicity. Excluded within 4 weeks of study entry: Immunomodulating agents, including steroids, interferon, Isoprinosine, and interleukin 2. Excluded within 8 weeks of study entry: Other antiretroviral agents (e.g., zidovudine [AZT], suramin, ribavirin, HPA23, foscarnet, dextran sulfate, disulfiram, ddA/ddC, or dideoxycytidine). Active drug or alcohol abuse.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1990</verification_date>
	<keyword>Kidney Failure, Chronic</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Renal Dialysis</keyword>
</DOC>